International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 137-144 , August 2010

Exposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria

  • D. Sevillano

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • L. Aguilar

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 394 1505; fax: +34 91 394 1511.
    • ,
  • L. Alou

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • M.J. Giménez

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • N. González

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • M. Torrico

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • F. Cafini

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • ,
  • C. Garcia-Rey

      Affiliations

    • Medical Department, Wyeth Farma S.A., Ctra. N-I, km. 23 Desvío Algete Km.1, San Sebastián de los Reyes, 28700 Madrid, Spain
    • ,
  • N. Garcia-Escribano

      Affiliations

    • Medical Department, Wyeth Farma S.A., Ctra. N-I, km. 23 Desvío Algete Km.1, San Sebastián de los Reyes, 28700 Madrid, Spain
    • ,
  • J. Prieto

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain

Received 27 November 2009 ,Accepted 10 March 2010.

References 

  1. Ku YH, Chuang YC, Yu WL. In vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. J Microbiol Immunol Infect. 2008;41:332–336
  2. Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A, et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother. 2008;62:1261–1264
  3. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl. 1):S13–S14
  4. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208–1215
  5. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant Gram-positive cocci. Eur J Clin Microbiol Infect Dis. 2008;27:3–15
  6. Saribas S, Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy. 2004;50:250–254
  7. Sorlózano A, Gutiérrez J, Salmerón A, Luna JD, Martínez-Checa F, Román J, et al. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum β-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents. 2006;28:532–536
  8. Conejo M, Hernàndez J, Pascual A. Comparative activity of tigecycline, cefepime and imipenem against clinical isolates of Klebsiella pneumoniae producing extended spectrum β-lactamases, plasmid-mediated AmpC-type β-lactamases or both, associated or not with porin deficiency. Clin Microbiol Infect 2007;13(Suppl. 1)/Int J Antimicrob Agents 2007;29(Suppl. 2):S199. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/25th International Congress of Chemotherapy (ICC) Congress, Munich, Germany; 31 March–3 April 2007 [Abstract no. 1733_290].
  9. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(Suppl. 1):i17–i28
  10. Moellering RC. Enterococcus species, Streptococcus bovis, and Leuconostoc species. In:  Mandell GL,  Bennett JE,  Dolin R editor. Mandell, Douglas, and Bennett principles and practice of infectious diseases. 6th ed.. Philadelphia, PA: Elsevier Churchill Livingstone; 2005;p. 2411–2421
  11. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10:13–21
  12. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39:2439–2444
  13. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–1094
  14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that growth aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
  15. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: NCCLS; 1999.
  16. González N, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, et al. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: an in vitro pharmacodynamic approach. J Antimicrob Chemother. 2009;63:1215–1222
  17. Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol. 2007;47:727–737
  18. Andrews JM. Microbiological assays. In:  Reeves DS,  Wise R,  Andrews JM,  White LO editor. Clinical antimicrobial assays. 1st ed.. Oxford, UK: Oxford University Press; 1999;p. 35–44
  19. Firsov AA, Saverino D, Ruble M, Gilbert D, Manzano B, Medeiros AA, et al. Predictors of effect of ampicillin–sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother. 1996;40:734–738
  20. White R, Friedrich L, Burgess D, Warkentin D, Bosso J. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40:904–908
  21. Munford RS. Sepsis, severe sepsis, and septic shock. In:  Mandell GL,  Bennett JE,  Dolin R editor. Mandell, Douglas, and Bennett principles and practice of infectious diseases. 6th ed.. Philadelphia, PA: Elsevier Churchill Livingstone; 2005;p. 906–926
  22. Renaud B, Brun-Buisson C ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia. A cohort and case–control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–1590
  23. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med. 1996;154:617–624
  24. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117–123
  25. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274:968–974
  26. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28:1079–1106
  27. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49:220–229
  28. Kresken M, Leitner E, Seifert H, Peters G, von Eiff C. Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis. 2009;28:1007–1011
  29. Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int J Antimicrob Agents. 2009;34:121–130
  30. US Food and Drug Administration. TYGACIL® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf [accessed 9 April 2010].
  31. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing. Version 9 January 2010. http://www.bsac.org.uk/_db/_documents/Version_9_January_2010_final.pdf [accessed 15 April 2010].
  32. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52:165–171
  33. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2009;53:2756–2761
  34. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, et al. Exposure–response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51:1939–1945
  35. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62(Suppl. 1):i11–i16
  36. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure–response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52:204–210
  37. Alou L, Giménez MJ, Cafini F, Aguilar L, Sevillano D, González N, et al. In vitro effect of the presence of human albumin physiological concentrations on tigecycline antibacterial activity against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother. 2009;64:1230–1233
  38. Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis. 2004;50:267–281
  39. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose. J Antimicrob Chemother. 2006;58:1221–1229

PII: S0924-8579(10)00154-8

doi: 10.1016/j.ijantimicag.2010.03.021

International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 137-144 , August 2010

Article Tools

* Image Usage & Resolution